Glucagon-like peptide-1 receptor agonists significantly affect the quality of bowel preparation for colonoscopy

Abstract

Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) affect gastrointestinal motility, slowing gastric emptying and colonic transit. GLP-1RAs have an impact on gastric residue before endoscopy, but only limited data are available regarding its effect on the adequacy of colonic preparation. We investigated the association between GLP-1RA use and inadequate bowel preparation (IBP) for colonoscopy.

Methods We performed a multicenter retrospective study with GLP-1RA cases matched with controls (using propensity scores for age, sex, diabetes mellitus [DM], obesity, and co-morbidities). Data on demographics, medication use, procedural indications, and colonoscopy findings were collected. IBP (“poor preparation” on Aronchik scale or Boston Bowel preparation scale <5) was the primary outcome.

Results 4876 patients treated with GLP-1RAs were included in the analysis and compared with 4876 controls selected from 333 648 patients without GLP-1RA use. Among the GLP-1RA patients, 10% (n = 487) had IBP compared with 197 (4%) of the control group (P<0.001). Subgroup analysis showed a higher rate of IBP among diabetic patients treated with GLP-1RA (284/2364 [12%]) than among diabetic patients without GLP-1RA treatment (118/2364 [5%]; P<0.001). Additionally, 203/2512 nondiabetic patients treated with GLP-1RAs had IBP (8%) compared with 79 of the nondiabetic non-GLP-1RA group (3%; P<0.001). On multivariate analysis, diabetes and GLP-1RA use were both found to be independent risk factors for IBP (odds ratio [OR] 1.4 and OR 2.7, respectively; both P<0.001).

Conclusion Our findings highlight the necessity for special attention and tailored recommendations for both diabetic and nondiabetic patients treated with GLP-1RAs in terms of colonic preparation prior to colonoscopy.

• References

• 1 Górriz JL, Soler MJ, Navarro-González JF. et al. GLP-1 receptor agonists and diabetic kidney disease: a call of attention to nephrologists. J Clin Med 2020; 9: 947
• 2 Friedrichsen M, Breitschaft A, Tadayon S. et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Ones Metab 2021; 23: 754-762
• 3 Hjerpsted JB, Flint A, Brooks A. et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab 2018; 20: 610-619
• 4 Marathe CS, Rayner CK, Jones KL. et al. Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Exp Diabetes Res 2011; 2011: 279530
• 5 Halim MA, Degerblad M, Sundbom M. et al. Glucagon-like peptide-1 inhibits prandial gastrointestinal motility through myenteric neuronal mechanisms in humans. J Clin Endocrinol Metab 2018; 103: 575-585
• 6 Stark JE, Cole JL, Ghazarian RN. et al. Impact of glucagon-like peptide-1 receptor agonists (GLP-1RA) on food content during esophagogastroduodenoscopy (EGD). Ann Pharmacother 2022; 56: 922-926
• 7 Silveira SQ, da Silva LM, de Campos Vieira Abib A. et al. Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy. J Clin Anesth 2023; 87: 111091
• 8 Bi D, Choi C, League J. et al. Food residue during esophagogastroduodenoscopy is commonly encountered and is not pathognomonic of delayed gastric emptying. Dig Dis Sci 2021; 66: 3951-3959
• 9 Yao R, Gala KS, Ghusn W. et al. Effect of glucagon-like peptide-1 receptor agonists on bowel preparation for colonoscopy. Am J Gastroenterol 2024; 119: 1154-1157
• 10 Tong Y, Huang JQ, Chen Y. et al. Impact of glucagon-like peptide 1 receptor agonist liraglutide and dipeptidyl peptidase-4 inhibitor sitagliptin on bowel cleaning and gastrointestinal symptoms in type 2 diabetes. Front Pharmacol 2023; 14: 1176206
• 11 Sharma T, Das N, Ismail B. et al. Evaluation of the effect of GLP-1 agonists on quality of bowel preparation for colonoscopy in patients with diabetes. Pract Diabetes 2017; 34: 167-168
• 12 Parmar R, Martel M, Rostom A. et al. Validated scales for colon cleansing: a systematic review. Am J Gastroenterol 2016; 111: 197-204
• 13 Lai EJ, Calderwood AH, Doros G. et al. The Boston bowel preparation scale: a valid and reliable instrument for colonoscopy-oriented research. Gastrointest Endosc 2009; 69: 620-625
• 14 Scalvini D, Lenti MV, Maimaris S. et al. Superior bowel preparation quality for colonoscopy with 1L-PEG compared to 2L-PEG and picosulphate: Data from a large real-world retrospective outpatient cohort. Dig Liver Dis 2024;
• 15 Yadlapati R, Johnston ER, Gregory DL. et al. Predictors of inadequate inpatient colonoscopy preparation and its association with hospital length of stay and costs. Dig Dis Sci 2015; 60: 3482-3490
• 16 Nguyen DL, Wieland M. Risk factors predictive of poor quality preparation during average risk colonoscopy screening: The importance of health literacy. J Gastrointest Liver Dis 2010; 19: 369-372
• 17 Romero RV, Mahadeva S. Factors influencing quality of bowel preparation for colonoscopy. World J Gastrointest Endosc 2013; 5: 39-46
• 18 Feng L, Guan J, Dong R. et al. Risk factors for inadequate bowel preparation before colonoscopy: A meta-analysis. J Evid Based Med 2024; 17: 341-350
• 19 Mahmood S, Farooqui SM, Madhoun MF. Predictors of inadequate bowel preparation for colonoscopy: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2018; 30: 819-826‏
• 20 Chung YW, Han DS, Park KH. et al. Patient factors predictive of inadequate bowel preparation using polyethylene glycol: a prospective study in Korea. J Clin Gastroenterol 2009; 43: 448-452
• 21 Taylor C, Schubert ML. Decreased efficacy of polyethylene glycol lavage solution (golytely) in the preparation of diabetic patients for outpatient colonoscopy: a prospective and blinded study. Am J Gastroenterol 2001; 96: 710-714
• 22 Vinik AI, Maser RE, Mitchell B. et al. Diabetic autonomic neuropathy. Diabetes Care 2003; 26: 1553-1579
• 23 Chirila A, Nguyen ME, Tinmouth J. et al. Preparing for colonoscopy in people with diabetes: a review with suggestions for clinical practice. J Can Assoc Gastroenterol 2022; 6: 26-36
• 24 Joshi G, Abdelmalak B, Weigel W. et al. American Society of Anesthesiologists consensus-based guidance on preoperative management of patients (adults and children) on glucagon-like peptide-1 (GLP-1) receptor agonists.. Accessed September 03, 2024 at: www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative
• 25 Multisociety statement. No data to support stopping GLP-1 agonists prior to elective endoscopy . 2023 Accessed September 03, 2024 at: https://gastro.org/news/gi-multi-society-statement-regarding-glp-1-agonists-and-endoscopy/
• 26 Hashash JG, Thompson CC, Wang AY. AGA rapid clinical practice update on the management of patients taking glp-1 receptor agonists prior to endoscopy: communication. Clin Gastroenterol Hepatol 2024; 22: 705-707
• 27 Kimber JS, Symonds E, Uylaki W. Exploring the associations between colorectal polyps and type 2 diabetes mellitus in a colonoscopy clinic population. ESMO Gastrointest Oncol 2024; 4: 100053
• 28 Xu J, He W, Zhang N. et al. Risk factors and correlation of colorectal polyps with type 2 diabetes mellitus. Ann Palliat Med 2022; 11: 647-654
• 29 Salimian S, Habibi M, Sehat M. et al. Obesity and incidence of colorectal polyps: a case-controlled study. Ann Med Surg (Lond) 2023; 85: 306-310
• 30 Ling S, Brown K, Miksza JK. et al. Association of type 2 diabetes with cancer: a meta-analysis with bias analysis for unmeasured confounding in 151 cohorts comprising 32 million people. Diabetes Care 2020; 43: 2313-2322
• 31 Vekic J, Zeljkovic A, Stefanovic A. et al. Diabetes and colorectal cancer risk: a new look at molecular mechanisms and potential role of novel antidiabetic agents. Int J Mol Sci 2021; 22: 12409
• 32 Seo JY, Jin EH, Chung GE. et al. The risk of colorectal cancer according to obesity status at four-year intervals: a nationwide population-based cohort study. Sci Rep 2023; 13: 8928
• 33 Wang L, Wang W, Kaelber DC. et al. GLP-1 receptor agonists and colorectal cancer risk in drug-naive patients with type 2 diabetes, with and without overweight/obesity. JAMA Oncol 2024; 10: 256-258
• 34 Tong G, Peng T, Chen Y. et al. Effects of GLP-1 receptor agonists on biological behavior of colorectal cancer cells by regulating PI3K/AKT/mTOR signaling pathway. Front Pharmacol 2022; 13: 901559